Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression

被引:39
作者
Schop, RFJ
Jalal, SM
Van Wier, SA
Ahmann, GJ
Bailey, RJ
Kyle, RA
Greipp, PR
Rajkumar, SV
Gertz, MA
Lust, JA
Lacy, MQ
Dispenzieri, A
Witzig, TE
Fonseca, R [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Div Hematol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA
关键词
D O I
10.1016/S0165-4608(01)00526-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Waldenstrom macroglobulinemia (WM) is a plasma cell dyscrasia characterized by a monoclonal IgM paraproteinemia. Deletions of 17p13.1 and 13q14 are associated with tumor progression and worsened outcome in multiple myeloma (MM), and we thus investigated WM patients for their presence. Patients (n = 40) were required to have a greater than or equal to1.5 g/dl serum IgM paraproteinemia and a monoclonal lymphoplasmacytic infiltrate. We used interphase fluorescence in situ hybridization (FISH) with probes that localized to 17p13.1(LSI p53/CEP 17) and 13q14 (D13S319 and LSI 13 Rb). Of 40 successfully studied patients for 17p13.1(p53) deletions, 6 were abnormal, consistent with hemizygous deletion (15%). Of 37 cases successfully studied for the 13q14 deletions, 6 were also abnormal with one pair of signals deleted (16%). Patients with deletions were more likely to be later in the course of the disease. No obvious clinical associations were noted with the exception that patients with 17p13.1(p53) deletions had a higher percent involvement of clonal cells in the bone marrow. Deletions of these two regions are uncommon in WM, being more common in the late stages of the disease, thus unlikely playing a role in primary disease pathogenesis. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 27 条
[1]   A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies [J].
Ahmann, GJ ;
Jalal, SM ;
Juneau, AL ;
Christensen, ER ;
Hanson, CA ;
Dewald, GW ;
Greipp, PR .
CANCER GENETICS AND CYTOGENETICS, 1998, 101 (01) :7-11
[2]   P53 deletion is not a frequent event in multiple myeloma [J].
Avet-Loiseau, H ;
Li, JY ;
Godon, C ;
Morineau, N ;
Daviet, A ;
Harousseau, JL ;
Facon, T ;
Bataille, R .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (03) :717-719
[3]   Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma [J].
Avet-Loiseau, H ;
Li, JY ;
Morineau, N ;
Facon, T ;
Brigaudeau, C ;
Harousseau, JL ;
Grosbois, B ;
Bataille, R .
BLOOD, 1999, 94 (08) :2583-2589
[4]   Construction of a 780-kb PAC, BAC, and cosmid contig encompassing the minimal critical deletion involved in B cell chronic lymphocytic leukemia at 13q14.3 [J].
BouygeMoreau, I ;
Rondeau, G ;
AvetLoiseau, H ;
Andre, MT ;
Bezieau, S ;
Cherel, M ;
Saleun, S ;
Cadoret, E ;
Shaikh, T ;
DeAngelis, MM ;
Arcot, S ;
Batzer, M ;
Moisan, JP ;
Devilder, MC .
GENOMICS, 1997, 46 (02) :183-190
[5]   Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia [J].
Bullrich, F ;
Veronese, ML ;
Kitada, S ;
Jurlander, J ;
Caligiuri, MA ;
Reed, JC ;
Croce, CM .
BLOOD, 1996, 88 (08) :3109-3115
[6]   Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia [J].
Corcoran, MM ;
Rasool, O ;
Liu, Y ;
Iyengar, A ;
Grander, D ;
Ibbotson, RE ;
Merup, M ;
Wu, XS ;
Brodyansky, V ;
Gardiner, AC ;
Juliusson, G ;
Chapman, RM ;
Ivanova, G ;
Tiller, M ;
Gahrton, G ;
Yankovsky, N ;
Zabarovsky, E ;
Oscier, DG ;
Einhorn, S .
BLOOD, 1998, 91 (04) :1382-1390
[7]   Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications [J].
Dierlamm, J ;
Michaux, L ;
Criel, A ;
Wlodarska, I ;
VandenBerghe, H ;
Hossfeld, DK .
CANCER GENETICS AND CYTOGENETICS, 1997, 94 (01) :27-35
[8]   Waldenstrom's macroglobulinemia: Clinical features, complications, and management [J].
Dimopoulos, MA ;
Panayiotidis, P ;
Moulopoulos, LA ;
Sfikakis, P ;
Dalakas, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :214-226
[9]  
Dohner H, 1997, LEUKEMIA, V11, pS19
[10]   Genomic aberrations and survival in chronic lymphocytic leukemia. [J].
Döhner, H ;
Stilgenbauer, S ;
Benner, A ;
Leupolt, E ;
Kröber, A ;
Bullinger, L ;
Döhner, K ;
Bentz, M ;
Lichter, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1910-1916